Updated: Novartis trims pipeline by 10% as Vas Narasimhan places premium on 'high-value medicines'
Novartis is shedding around 10% of its pipeline as Vas Narasimhan’s campaign to turn it into a “pure-play” drugmaker goes full steam.
Following a “comprehensive review of R&D projects” during the first quarter of 2023, the Swiss company said in its quarterly update that it’s decided to discontinue or out-license projects for considerations like strategic fit, asset value, commercial potential and competitive landscape.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.